These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 25436793)

  • 1. BRAF mutations in non-small-cell lung cancer.
    Smit E
    J Thorac Oncol; 2014 Nov; 9(11):1594-5. PubMed ID: 25436793
    [No Abstract]   [Full Text] [Related]  

  • 2. BRAF
    Rosell R; Karachaliou N
    Lancet Oncol; 2017 Oct; 18(10):1286-1287. PubMed ID: 28919012
    [No Abstract]   [Full Text] [Related]  

  • 3. BRAF mutations in non-small cell lung cancer: has finally Janus opened the door?
    Caparica R; de Castro G; Gil-Bazo I; Caglevic C; Calogero R; Giallombardo M; Santos ES; Raez LE; Rolfo C
    Crit Rev Oncol Hematol; 2016 May; 101():32-9. PubMed ID: 26960735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations.
    Tissot C; Couraud S; Tanguy R; Bringuier PP; Girard N; Souquet PJ
    Lung Cancer; 2016 Jan; 91():23-8. PubMed ID: 26711930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Mutation of the BRAF genes in non-small cell lung cancer].
    Huang Z; Wu Y
    Zhongguo Fei Ai Za Zhi; 2012 Mar; 15(3):183-6. PubMed ID: 22429583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAF V600E mutations: a series of case reports in patients with non-small cell lung cancer.
    Goldman JM; Gray JE
    Cancer Genet; 2015 Jun; 208(6):351-4. PubMed ID: 26066373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A patient diagnosed with BRAF-mutated non-small cell lung cancer and hairy cell leukemia: at last, which entity is really carrying the BRAF mutation?
    Schlick K; Troch M; Placher-Sorko G; Faber V; Neureiter D; Berghoff AS; Preusser M; Greil R; Hopfinger G
    Ann Hematol; 2015 Feb; 94(2):345-6. PubMed ID: 25055797
    [No Abstract]   [Full Text] [Related]  

  • 8. Somatic mutation analysis of KRAS, BRAF, HER2 and PTEN in EGFR mutation-negative non-small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel deletion in HER2 gene from Indian patients.
    Bhaumik S; Ahmad F; Das BR
    Med Oncol; 2016 Oct; 33(10):117. PubMed ID: 27637917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KRAS and BRAF Double Mutations and Functional Classes of BRAF Mutations in Non-small-cell Lung Cancers.
    Bourhis A; Remoué A; Uguen A
    Clin Lung Cancer; 2020 Jul; 21(4):e240-e242. PubMed ID: 32253111
    [No Abstract]   [Full Text] [Related]  

  • 10. A BRAF new world.
    Frisone D; Friedlaender A; Malapelle U; Banna G; Addeo A
    Crit Rev Oncol Hematol; 2020 Aug; 152():103008. PubMed ID: 32485528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Survival of a Patient With Non-Small-Cell Lung Cancer Harboring a V600E Mutation in the BRAF Oncogene.
    Myall NJ; Neal JW; Cho-Phan CD; Zhou LY; Stehr H; Zhou L; Diehn M; Wakelee HA
    Clin Lung Cancer; 2016 Mar; 17(2):e17-21. PubMed ID: 26776917
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical significance of BRAF gene mutations in patients with non-small cell lung cancer.
    Kobayashi M; Sonobe M; Takahashi T; Yoshizawa A; Ishikawa M; Kikuchi R; Okubo K; Huang CL; Date H
    Anticancer Res; 2011 Dec; 31(12):4619-23. PubMed ID: 22199339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF-mutations in non-small cell lung cancer.
    Brustugun OT; Khattak AM; Trømborg AK; Beigi M; Beiske K; Lund-Iversen M; Helland Å
    Lung Cancer; 2014 Apr; 84(1):36-8. PubMed ID: 24552757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of consistency of detecting BRAF gene mutations in peripheral blood and tumor tissue of nonsmall-cell lung cancer patients.
    Fang M; Xu C; Wu J; Zhang Y; He C
    J Cancer Res Ther; 2014 Nov; 10 Suppl():C150-4. PubMed ID: 25450274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF Mutations-A Good News Story for Immune Checkpoint Inhibitors in Oncogene-Addicted NSCLC?
    Arulananda S; Mitchell P
    J Thorac Oncol; 2018 Aug; 13(8):1055-1057. PubMed ID: 30056857
    [No Abstract]   [Full Text] [Related]  

  • 16. Molecular alterations in non-small cell lung carcinomas of the young.
    VandenBussche CJ; Illei PB; Lin MT; Ettinger DS; Maleki Z
    Hum Pathol; 2014 Dec; 45(12):2379-87. PubMed ID: 25288236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted treatment for lung cancer could be possible due to identification of nonuniform genetic mutations.
    Jones S
    Pharmacogenomics; 2014 May; 15(7):903-4. PubMed ID: 25090664
    [No Abstract]   [Full Text] [Related]  

  • 18. Analysis of KRAS and BRAF genes mutation in the central nervous system metastases of non-small cell lung cancer.
    Nicoś M; Krawczyk P; Jarosz B; Sawicki M; Szumiłło J; Trojanowski T; Milanowski J
    Clin Exp Med; 2016 May; 16(2):169-76. PubMed ID: 25902737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testing epidermal growth factor receptor mutations in patients with non-small-cell lung cancer to choose chemotherapy: the other side of the coin.
    Garassino MC; Marsoni S; Floriani I
    J Clin Oncol; 2011 Oct; 29(28):3835-7; author reply 3837-9. PubMed ID: 21876080
    [No Abstract]   [Full Text] [Related]  

  • 20. Economic analysis of BRAF gene mutation testing in real world practice using claims data: costs of single gene versus panel tests in patients with lung cancer.
    Dalal AA; Guerin A; Mutebi A; Culver KW
    J Med Econ; 2018 Jul; 21(7):649-655. PubMed ID: 29516752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.